What is Gland Pharma?
Established in 1978 and headquartered in Hyderabad, India, Gland Pharma has evolved into a critical manufacturer of generic injectables. The company operates on a sophisticated business-to-business model, providing essential pharmaceutical solutions to healthcare providers in over 60 countries, including the United States, Europe, and Australia. By specializing in high-barrier segments such as oncology and ophthalmics, Gland Pharma leverages its extensive R&D infrastructure to maintain a competitive edge. Its manufacturing prowess is central to its mission of delivering affordable, high-quality medical products that address the complex needs of the modern healthcare industry.
How much funding has Gland Pharma raised?
Gland Pharma has raised a total of $200M across 1 funding round:
Unspecified
$200M
Unspecified (2013): $200M with participation from KKR & Co. L.P.
Key Investors in Gland Pharma
KKR & Co. L.P.
KKR is a global investment firm investing across private markets in every asset class all over the world. Their mission is to fortify companies and communities and help secure the futures of the institutions and individuals counting on them.
What's next for Gland Pharma?
Following this major strategic investment, Gland Pharma is well-positioned to accelerate its growth trajectory and deepen its penetration into key international markets. The infusion of capital is expected to support the expansion of its R&D facilities and the optimization of its global supply chain. As the pharmaceutical sector continues to demand high-quality, cost-effective injectable solutions, Gland Pharma's focus on operational excellence and product diversification will likely serve as a catalyst for sustained long-term value creation. The company remains dedicated to navigating the evolving regulatory landscapes of its target regions while maintaining its reputation as a reliable partner in the global pharmaceutical supply chain.
See full Gland Pharma company page
